A Novel Surface Electrocardiogram Based Marker of Ventricular Arrhythmia Risk in Patients with Ischemic Cardiomyopathy

William B. Nicolson MRCP\textsuperscript{1,2}, Gerry P. McCann MD, MRCP\textsuperscript{2,3}, Peter D. Brown MRCP\textsuperscript{1}, Alastair J Sandilands PhD, MRCP\textsuperscript{3}, Peter J Stafford MD, FRCP\textsuperscript{3}, Fernando S Schlindwein PhD DSc\textsuperscript{3}, Nilesh J Samani MD, FRCP\textsuperscript{1,2,3}, G. André Ng PhD, FRCP\textsuperscript{1,2,3}

Affiliations

\textsuperscript{1}Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
\textsuperscript{2}NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, UK
\textsuperscript{3}University Hospitals of Leicester NHS Trust, Leicester, UK
\textsuperscript{4}Department of Engineering, University of Leicester, Leicester, UK

First Author's Surname: Nicolson

Short Title: Novel Surface ECG marker of Ventricular Arrhythmia

Correspondence

Dr G. André Ng
Department of Cardiovascular Sciences
University of Leicester, Glenfield Hospital,
Leicester, LE3 9QP, UK
Telephone: +44(0)1162583297 Fax: +44(0)1162875792
E-mail: gan1@le.ac.uk
Word count: 6007

Abstract

**Background:** Better sudden cardiac death risk markers are needed in ischemic cardiomyopathy (ICM). Increased heterogeneity of electrical restitution is an important mechanism underlying the risk of ventricular arrhythmia (VA). The aim was to develop and test a novel quantitative surface electrocardiogram based measure of ventricular arrhythmia risk in patients with ischemic cardiomyopathy, the Regional Restitution Instability Index (R2I2).

**Methods and Results:** R2I2, mean of standard deviation of residuals from the mean gradient for each ECG lead at a range of diastolic intervals, was measured retrospectively, from high resolution 12 lead ECG recorded during an electrophysiology study (EPS). Patient groups were: Study group: 26 ICM patients being assessed for implantable defibrillator; Control group: 29 supraventricular tachycardia patients undergoing EPS; Replication group: 40 further ICM patients. R2I2 was significantly higher in the Study group than Controls (mean±SEM: 1.09±0.06 vs. 0.63±0.04, p<0.001). Over median follow-up of 23 months, 6/26 Study group patients had VA/death. R2I2 predicted VA/death independent of demographic factors, EPS result, left ventricular ejection fraction or QRS duration (Cox model, p=0.029). R2I2 correlated with peri-infarct zone assessed by cardiac magnetic resonance imaging (r=0.51, p=0.024). The Replication group replicated findings: R2I2 was significantly higher in 11/40 Replication patients experiencing VA (1.18±0.10 vs. 0.92±0.05, p=0.019). In combined analysis of ICM cohorts, R2I2>1.03 identified subjects with significantly higher risk of VA/death (43%) compared with R2I2 below 1.03 (11%) (p=0.004).

**Conclusions:** In this pilot study, we have developed a novel VA risk marker, R2I2, and shown that it correlated with a structural measure of arrhythmic risk and predicted risk of VA/death in patients with ICM. R2I2 may improve risk stratification and merits further evaluation.

**Key Words:**
death, sudden; electrical restitution; risk factors; implantable cardioverter defibrillator; electrocardiography
Abbreviations:

APD = action potential duration
CMR = cardiac magnetic resonance imaging
ECG = electrocardiogram
EPS = electrophysiological study
ICD = implantable cardioverter defibrillator
ICM = ischemic cardiomyopathy
PIZ = peri-infarct zone
QTp = QRS onset to T wave peak
QTe = QRS onset to T wave end
R2I2 = regional restitution instability index
SCD = sudden cardiac death
TpQ = T wave peak to QRS onset
TpTe = T wave peak to T wave end
VA = ventricular arrhythmia
Introduction

Sudden cardiac death (SCD) is responsible for over 3 million deaths per year worldwide. Implantable cardioverter defibrillators (ICDs) are of proven benefit in preventing SCD. However, SCD risk assessment has considerable limitations despite 20 years of research. In MADIT II and SCD-HeFT <40% of patients received appropriate ICD shock therapy during the first 4 years of follow up,[3,4], while the majority of SCD occurs in the large population of people who, based on current evidence, are stratified as being at “low risk”.[3]

Ventricular arrhythmia (VA) risk is known to be associated with heterogeneity of repolarisation.[4,5] Increasing evidence from computer and animal models now implicates increased heterogeneity of electrical restitution as an important arrhythmogenic mechanism.[6] Action potential duration (APD) restitution describes a myocardial property whereby APD is determined by the preceding diastolic interval. Body surface measurement of APD restitution has been shown to be possible in a small canine study using a single electrocardiogram (ECG) lead and has been correlated with epicardial unipolar electrograms.[7,8]

The aim of this retrospective study was to develop a new electrophysiological measure of electrical restitution heterogeneity using the surface ECG: the Regional Restitution Instability Index (R2I2), to assess its correlation with cardiac magnetic resonance (CMR) features of increased VA risk and to test and replicate its utility in predicting risk of VA/death in patients with ischemic cardiomyopathy (ICM) who were candidates for ICD therapy.[9-11]

Methods

Subjects

Ethical approval for this study was sought but deemed unnecessary by the Leicestershire Research Ethics Committee and the study protocol was approved by the Research and Development Office of
the University Hospitals of Leicester National Health Service Trust. The Primary Study group was identified by screening the Cardiology Department’s audit databases for patients with a history of ICM who had undergone an electrophysiology study (EPS) with programmed electrical stimulation between 1st January 2005 and 31st July 2009 as part of clinical risk stratification for ICD implantation (in accordance with UK guidelines) and who had also had a CMR scan within 6 months of their EPS. This identified 43 patients. EPS recordings were unavailable for 9 patients and 4 more patients were excluded because only 6 lead surface ECGs had been recorded. Of the 30 patients for whom EPS data was available 3 were excluded from analysis because of insufficient data due to non-captured beats and 1 could not be analysed because the drive cycle length was changed midway through the protocol. CMR data was then sought for the remaining 26 patients. Late gadolinium enhanced CMR images were not acquired for 3 patients because of difficulties gating (1) and breath holding (2) and 4 patients could not be analysed because of an incompatibility between the acquisition and peri-infarct zone analysis software. Late gadolinium enhanced CMR images were available for 19/26 patients.

A 30 patient Control group was selected from patients who had had an EPS for supraventricular tachycardia in 2010. Case matching was performed where possible on the basis of age and gender. Controls were excluded prior to data analysis if they had: insufficient surface ECG data recorded, an abnormal echocardiogram, atrial fibrillation, family history of SCD or diabetes mellitus (because of potential for associated autonomic dysfunction and silent ischemic heart disease). During data analysis one Control was excluded because it was apparent that the quadripolar catheter had moved from the right ventricular apex during the study. All Control subjects had normal left ventricular function as judged by visual assessment of 2D transthoracic echoes. The Replication ICM group was selected in the same way as the Primary Study group, except that only patients who had ICD implantation were selected and a CMR scan was not required; this identified 40 patients.
Electrophysiological Study

EP studies were performed as per the standard departmental protocol, which did not change for the duration of the study. Fasting subjects were studied with minimal sedation and with antiarrhythmic drug cessation 4-5 half-lives prior to the procedure. Data was recorded using a 6F quadripolar catheter advanced transvenously to the right ventricular apex; other catheters were positioned as appropriate to the clinical procedure. Standard 12 lead electrocardiograms were recorded using LabSystem Pro (BARD, Lowell) at 1 kHz sampling rate with a low pass filter set to 50Hz and high pass filter set to 0.01Hz. The study protocol used an 8 or 10 beat train at drive cycle lengths of 600ms and 400ms. A single extrastimulus protocol was followed with decrements of 20ms. If breakthrough beats were seen in the drive train the drive cycle length was reduced. The S1S2 coupling interval is the period between the last beat of the drive train and the first extrastimulus, the R2I2 was derived from measurements taken from the last S1 and the S2 beats. Programmed electrical stimulation was performed in the Primary Study and Replication cohorts; a modified Wellens protocol was used (two drive trains, drive cycle length 600ms and 400ms, at the right ventricular apex and one, drive cycle length 400ms, at the right ventricular outflow tract coupled with up to 3 extrastimuli with each drive train). Monomorphic ventricular tachycardia of duration greater than 30 seconds or associated with hemodynamic compromise was recorded as positive; the test was otherwise recorded as negative.

Analysis of the R2I2

The surface electrocardiograms were exported at 16-bit digital resolution for analysis in custom software written in MATLAB (Mathworks, Natick) by WBN. The timing of the QRS onset and T wave peak were analysed automatically and all data points were manually verified by WBN, a senior electrophysiology research fellow. The T wave peak was chosen in preference to the end of the T wave because of the known difficulties in measuring the end of the T wave. The R2I2 is derived from the QRS onset and T wave peak measurements. Intra and inter-operator reproducibility was
assessed using a representative sample of 242 paced ECG points from the dataset and was performed independently by two electrophysiology research fellows (WBN and PDB). Mean intra-operator variability for measurement of the QRS onset and T wave peak was 5.0ms (SD 7.6ms) vs. inter-operator 6.0ms (SD 7.9ms).

Data points were censored according to predetermined rules: 1. Breakthrough beat occurring after beat 6 of the drive train (146/1114 drive train beats censored), 2. Point indeterminate due to artefact, baseline wander or unclear morphology (536/11758 points). For each S1 S2 coupling interval the diastolic interval was taken as the period from T wave peak on the last beat of the drive train to the S2 QRS onset (TpQ), as shown in Figure 1; note the possibility for negative T wave peak to QRS onset interval as measured in this way. The body surface surrogate for the action potential duration was taken as the period from S2 QRS onset to the S2 T wave peak(QTp). These body surface surrogates were measured for each S2 performed at the right ventricular apex; where possible drive trains with drive cycle length 600ms were used but if not present or unusable due to breakthrough beats an alternative drive cycle length was selected.

The focus of the study was on regional electrical heterogeneity assessed by APD restitution gradient. For each lead of the surface ECG the QTp was plotted as a function of TpQ and gradients were fitted using 40ms overlapping least squares linear segments as described previously by Taggart et al. (Figure 2). For each lead, in each 40ms segment, the difference of the gradient from the mean gradient in that 40ms segment was calculated. The standard deviation of these values was taken as a measure of APD heterogeneity in each lead. The mean of this was then taken as the R2I2 (no units). A small number of non-physiologically steep gradients result from points that have near or identical TpQ (measured to the nearest millisecond). To avoid skewing of the data, gradients exceeding ±10 were censored (1.5% of gradients).
Measurement of T wave peak to T wave end interval and QT Dispersion

The exported ECGs were also used to measure non-paced T wave peak to T wave end intervals (TpTe) and QT dispersion. As described by Chugh et al. TpTe was measured in lead V5, or if V5 was not suitable due to noise or low amplitude V4 or V6 were used in that order.\(^{16}\) Tend was taken to be the intersection of the tangent to the down slope of the T wave and the isoelectric line. If a U wave followed the T wave, the T-wave offset was measured as the nadir between the T and U waves. The QT interval was measured from the earliest onset of the QRS complex to the end of the T wave. The QT dispersion for each ECG recording was defined as the difference between the longest and shortest measured QT interval.\(^{17}\)

Late Gadolinium Enhanced Cardiac Magnetic Resonance Imaging Protocol

The ICM patients in the Primary Study cohort underwent late gadolinium enhanced CMR as per Departmental protocol within a median of 35 days [inter-quartile range 105 days] of their EPS. Comprehensive CMR imaging was performed using a 1.5-T scanner (Siemens Magnetom, Avanto) with ECG triggering and a 6 channel phased array cardiac coil. After scout imaging, steady-state free precession (TrueFISP) cine images were acquired in 4, 3 and 2 chamber-views and a series of short axis slices were obtained covering the left ventricle from base to apex, with 1 slice every 10mm.\(^{18}\) A gadolinium-based contrast agent (0.1-0.2mmol/kg) was administered intravenously as a bolus and late gadolinium enhanced images were obtained approximately 10 minutes later with the use of an inversion-recovery, segmented gradient echo sequence.\(^{19,20}\)

CMR analysis

All analysis was performed offline blinded to patient details using commercially available software. Volumetric analysis was performed by manual tracing of endocardial and epicardial contours; left ventricular end-diastolic volume, end-systolic volume, stroke volume, left ventricular ejection fraction and left ventricular end-diastolic mass were calculated. Late gadolinium enhanced images
were analysed for scar and peri-infarct zone mass using a modification of the Schmidt et al technique. All voxels with signal intensity greater than 50% of peak infarct core were recorded as scar. PIZ was defined as all pixels in the region of the myocardial infarction with signal intensity >2 standard deviations above mean intensity in an area of normal myocardium and below 50% of the peak intensity (Figure 3). CMR volumes and mass were indexed to height. Scar size is presented as percent of left ventricular mass and PIZ as mass in grams, percent of left ventricular mass and percent of infarct size.

**Statistical analysis**

Parametric data are expressed as mean ± standard error of the mean and analysed using Student’s t-test; non-parametric data as median [inter-quartile range] and analysed using the Mann-Whitney U test. Proportions were analysed using a two-sided Fisher’s exact test. A receiver operator characteristic curve using the R2I2 was constructed in the Primary Study cohort for identification of the optimal R2I2 cut-off and for comparison in the Replication cohort. A Kaplan-Meier survival curve was drawn using this cut-off value, combining the Primary Study and Replication groups; comparison of cumulative endpoints was based on logarithmic transformations. Survival was recorded as time to first endpoint or the end of follow up. Pearson rank correlation was used to look for correlation between the R2I2 and PIZ and between age and R2I2 within the Control, Primary Study and Replication groups and between R2I2 and TpTe in the combined ICM cohorts. Spearman’s rank correlation was used to look for correlation between R2I2 and QT dispersion in the combined ICM cohorts. A single Cox proportional hazards model was used to look for independence of the R2I2, programmed electrical stimulation result, left ventricular ejection fraction and QRS duration in the Primary Study group. A p-value <0.05 was considered statistically significant. All analyses were performed using STATA (StataCorp LP, College Station).
Results

The clinical characteristics, and relevant ECG characteristics including mean R212 values for the 26 Primary Study group patients, the 29 Controls and the 40 Replication group patients are summarised in Table 1. Given that the Controls underwent an EPS because of a different indication (supraventricular tachycardia), there were significant differences in their clinical characteristics and left ventricular ejection fraction compared to the two other groups. Individual level R212 values for subjects of all three groups are shown in Figure 4. R212 was significantly greater in the Primary Study group compared with the Controls (1.09±0.05 vs. 0.63±0.04 p<0.001). No correlation was seen between age or gender and the R212 within the Primary Study, Control or Replication groups.

Median follow up in the Primary Study group was 23 months [18] during which 6 patients reached the endpoint of VA/death: 3 VA and 4 deaths (1 patient had successful ICD therapy for VA and subsequently died). Following programmed electrical stimulation 12/26 Primary Study group patients had ICDs implanted and 2/4 deaths occurred in patients who did not have ICDs. Characteristics of the Primary Study Group patients partitioned on the basis of the primary endpoint are shown in Table 2. Patients who reached an endpoint had significantly higher mean R212 than those that did not (1.30±0.10 vs. 1.03±0.06 p=0.037). Age and programmed electrical stimulation result also trended towards an association with VA/death but were not correlated with R212. Cox multivariate analysis including the R212, programmed electrical stimulation result, left ventricular ejection fraction and QRS duration showed that the R212 was an independent predictor of VA/death (p=0.029).

The percentage of CMR PIZ was significantly associated with VA/death (15.6% [4.6] vs. 7.4% [8.0], p=0.016) and exhibited significant correlation with the R212 (r=0.51, p=0.024, Figure 5). Other CMR parameters such as scar percentage were also significantly associated with VA/death (22.0% [3.8] vs.
A receiver operating characteristic analysis of the Primary Study Group showed that a $R_2I_2$ cut-off of 1.03 provided the greatest discrimination between those who had a primary endpoint and those without an event during follow-up (area under curve of 0.792, Figure 6). Interestingly, none of the Control patients had a $R_2I_2$ value above 1.03 (Figure 4).

The Replication group did not differ significantly from the Primary Study group in the main clinical characteristics (Table 1). The Replication cohort subjects were selected on the basis of ICD implant; therefore the endpoint of VA was chosen. Median follow up in the Replication cohort was 40 months [22] during which 11 patients reached the primary endpoint of VA and 7 patients died. The Replication cohort replicated the findings of the Primary Study group: patients reaching the endpoint of VA had a significantly higher mean $R_2I_2$ (1.18±0.10 vs. 0.92±0.05 $p=0.019$). A $R_2I_2$ cut-off value of 1.03 identified 7/11 patients who suffered an endpoint, the receiver operating characteristic area under curve was 0.740.

In a combined analysis of the ICM subjects from the Primary Study and Replication groups, an $R_2I_2$≥1.03 identified subjects with a significantly higher risk of VA/death (43%, 13/30) compared with those with an $R_2I_2$ below 1.03 (11%, 4/36) ($p=0.004$, Fisher’s exact). A survival curve of the combined ICM groups partitioned by an $R_2I_2$ value of 1.03 is shown in Figure 7; a highly significant difference ($p=0.003$, log rank) was observed. Side-by-side analysis of the $R_2I_2$ against $T_pTe$ and QT dispersion was performed using the combined ICM cohorts. In comparison of ICM patients experiencing VA/death versus ICM patients not reaching endpoint, neither $T_pTe$ (88.8 [32.7] vs. 77.2 [34.5], $p=0.644$) nor QT dispersion (66.3±32.8 vs. 60.0±25.9, $p=0.428$) were associated with endpoint. There was also no correlation between $R_2I_2$ and $T_pTe$ ($r=-0.004$, $p=0.978$) or between $R_2I_2$ and QT dispersion ($r=-0.207$, $p=0.096$).
Discussion

In this paper we report the development and characterisation of R2I2 as a potential prognostic marker in patients with ICM at risk of SCD. Despite considerable effort no definitive surface ECG marker of SCD risk has emerged to date. For example, microvolt T-wave alternans showed initial promise but in the 490 patient sub-study of SCD-HeFT, no significant difference in event free survival was found between microvolt T-wave alternans positive and negative patients (hazard ratio 1.24, 95% CI 0.60 to 2.59, P=0.56). Another technique is the signal-averaged ECG which combines a series of QRS complexes to detect ventricular late potentials which are thought to correlate with VA risk. However, in CAGB Patch, a 900 patient ICD prophylaxis trial, the signal-averaged ECG was unhelpful in identifying a high-risk group of patients. 22 R2I2 is a novel approach, founded on improved basic science understanding of VA,6,23 which has the potential to be further refined and offer clinical utility.

In the Primary Study group the R2I2 was significantly higher in patients with ischemic cardiomyopathy who subsequently had a VA or died. This result was replicated using a Replication cohort of patients with ICM and the predefined endpoint of VA. The R2I2 electrical measure of risk showed a significant, moderate correlation with an anatomic measure of arrhythmic substrate, the extent of PIZ. Importantly R2I2 was independent of programmed electrical simulation result, left ventricular ejection fraction and QRS duration suggesting that it may add value to existing markers of VA / death risk.

Simulation studies of ventricular fibrillation suggest that it is initiated by breaking of the depolarisation wave into multiple wavelets that spread chaotically. 24 Wavelets are extinguished if they collide with each other or are blocked by refractory tissue. Hence, according to this paradigm ventricular fibrillation is maintained by the constant genesis of new wavelets. The electrical
restitution properties of the heart have been linked to increased susceptibility to wavelet breakdown and generation of ventricular fibrillation. The relationship of the APD and conduction velocity of a certain beat to the diastolic interval from the previous beat has been shown both mathematically to be important and biologically to support a link with arrhythmogenesis. Regional heterogeneity of APD restitution adds to this electrical instability. Chronic myocardial infarction creates a complex milieu of heterogeneities in these electrical restitution properties. First, there is an underlying normal variation in APD restitution that is seen from base to apex, epicardium to endocardium and left to right ventricle. Heterogeneous behaviour of APD restitution in different regions of the heart has been demonstrated using intracardiac catheters and also with an epicardial sock of electrodes in patients undergoing cardiac surgery, with significant differences seen between patients with ischemic heart disease and aortic valve disease. Second, there is the anatomical heterogeneity related to interdigitation of infarcted and viable tissue and the effects of fibrosis on myofibril disarray and in particular conduction velocity restitution. Finally there are the many sequelae of ischaemia and myocardial insufficiency, for example, on APD and conduction velocity restitution curves and on the secretion of nerve growth factor leading to cardiac nerve sprouting and sympathetic hyperinnervation.

A high resolution 12 lead electrocardiogram describes the summation of myocyte electrical activity along specific vectors. Cardiac depolarisation flows in a complex 3 dimensional wave that is influenced by static factors such as myocardial scar and dynamic factors that exert their influence through APD and conduction velocity restitution. The diastolic interval, which itself has a spatial gradient, affects the excitability of individual myocytes, regional conduction velocity and also repolarisation. These effects alter the depolarisation wavefront, the consequence of this being dependent on whether the resulting wavelets propagate or are extinguished. In turn these effects will create spatial dispersion of repolarisation and potentially discordant alternans. The R212 attempts to use the 12 lead ECG to measure regional manifestations of this irreducibly complex
cardiac choreography. Figure 8 shows an example of regional differences in repolarisation developing as the S1-S2 coupling interval shortens in a Primary Study group patient who went on to develop VA; these changes cause substantial heterogeneity in the restitution gradient and a high R2I2 (1.63).

The R2I2 uses the T wave peak as a surrogate for end repolarisation rather than the more typically used T wave end as detection of the former is more accurately determined than the latter. Antzelevitch et al. suggest that the T wave peak correlates with end repolarisation of epicardial cells with the difference between the Tpeak and Tend (TpTe) reflecting transmural heterogeneity. Other authors consider the TpTe to reflect total left ventricular dispersion of repolarisation. It may be that the QTp interval is as reflective of the intracardiac APD as the QT end interval; the measures corresponding to different components of the signal. Sundqvist et al. investigated the relationship between QTp and QT e during exercise in healthy subjects and found that the QTp and QT e decrease in parallel with increasing heart rate and that the majority of the decrease is in the QTp rather than the TpTe. Haapalahti et al. have constructed QTp/heart rate slopes in control subjects and found them to be no different from QT e/heart rate slopes; they go on to find QTp autonomic responses in long QT syndrome 1 carriers to be more impaired than QT e responses. Important further work is needed to clarify the relationship between the R2I2 and intracardiac heterogeneity of restitution. Clinical studies by Chugh et al. and others have shown the TpTe interval to be a potentially useful predictor of sudden cardiac death and we will be actively assessing this measure and the QT e interval in future work.

For the electrophysiologist, the recent interest of the CMR community in assessing arrhythmia vulnerability through measurement of the PIZ is conceptually attractive. While this approach is still at an early stage, it has been shown in a study of 144 patients post myocardial infarction to be independent of left ventricular ejection fraction in its association with all cause mortality (p=0.005)
and it has also been found that PIZ predicted a positive programmed electrical stimulation test in 47 patients (p=0.015). Importantly late gadolinium enhanced CMR anatomical data has been shown to correlate with intracardiac CARTO voltage data, histology and cellular biochemical pathology. Limitations of PIZ quantification include spatial resolution of CMR (typically >1mm) the range of methods used to delineate it, the different ways in which measured PIZ is expressed and the tendency of PIZ research to use programmed electrical simulation result as an endpoint. In the current study we found a statistically significant correlation between PIZ and the R2I2 that offers further support for our hypothesis that R2I2 is an appropriate measure of electrical heterogeneity and of SCD risk.

The Replication cohort provided independent support for the efficacy of the R2I2 in predicting VA risk. While this is encouraging, further work is needed to identify the potential role of the R2I2 in ICD risk stratification, especially in prospective studies. It would be interesting to perform side-by-side analysis of the R2I2 with other ECG markers of SCD, for example, QT variability and T-wave alternans. This being a retrospective study, analysis of comparators was limited but it is of note that there is no correlation between QT dispersion, a conceptually flawed measure of repolarisation heterogeneity, and the R2I2. There has recently been interest in use of TpTe measurements with Chugh et al. presenting encouraging data. In the current study, which represents a comparatively small cohort, TpTe values are higher in patients experiencing VA/death but the result does not approach significance. The R2I2 does not correlate with the TpTe; the indices are substantially different with R2I2 using TpQ and QTp to measure restitution gradient heterogeneity across the 12 lead ECG and TpTe measuring repolarisation heterogeneity in a single lead. However, the TpTe component of repolarisation is potentially important and as previously mentioned we will be investigating TpTe and QTte in future work. There is scope for refining R2I2 and improving its accuracy. For example, decreasing the S1S2 coupling interval in 10ms steps from 300ms could provide more detail in the steep portion of the curve. Work is also needed to validate the R2I2
against intracardiac data. Finally, whether determination of R2I2 could be undertaken entirely non-invasively using exercise or chronotropic medication to induce a range of heart rates needs to be tested.

**Limitations**

This is a small retrospective study and has several limitations. The R2I2 in its current form is invasive, requiring intracardiac pacing to create a spectrum of diastolic intervals. Only 19/26 patients’ CMR scans were analysable. If the R2I2 data had been collected prospectively we would have used a longer drive train and repeated drive trains that had breakthrough beats in addition to performing a dynamic restitution protocol. Multivariate analysis was limited by the small numbers.

**Conclusions**

This pilot study suggests that the R2I2 is capable of extracting information on regional restitution heterogeneity and that this is increased in patients with ICM and associated with VA / death. Further work is needed to refine the technique and explore the correlation between the R2I2 and intracardiac APD and conduction velocity restitution and their clinical significance in patients with ICM.

**Acknowledgements**

This study is part of the research portfolio supported by the NIHR Leicester Cardiovascular Biomedical Research Unit (BRU).

**Funding Sources**

WBN was funded by a grant from the NIHR Leicester Cardiovascular BRU and by a Sorin PLC grant-in-aid. Additional funding was provided by a Da Vinci Clinical Impact award. NJS is supported by a Chair funded by the British Heart Foundation and is also a NIHR Senior Investigator.

**Disclosures**
Dr Will Nicolson is supported by a Sorin PLC Grant-in-aid. The University of Leicester has applied for a patent for the Regional Restitution Instability Index technique on behalf of Dr Will Nicolson and Dr G André Ng.

References


Figure Legends

Figure 1. Technique for measurement of diastolic interval surrogate: T wave peak to QRS onset (TpQ) and action potential duration surrogate: QRS onset to T wave peak (QTP). A. When an S2 arrives after the T wave peak the TpQ and QTP are measured as shown on the left of the diagram. B. If the S2 occurs before the T wave peak the TpQ is effectively negative. In this case it is measured by subtracting the QTP-1 interval (QTP for the last drive cycle beat) from the QP, in the example above this would give a TpQ close to zero.

Figure 2. Explanation of the R2I2 calculation and demonstration of the body surface restitution relation. A. Plot of QRS onset to T wave peak (QTP) against T wave peak to QRS onset (TpQ) for representative ECG leads: I (lateral), II (inferior) and V2 (anterior) to explain the Regional Restitution Instability Index (R2I2) calculation in a typical study patient. For each lead, the QTP / TpQ gradient (least squares regression) was calculated over a 40 ms segment of TpQ range. This segment was then scanned over the range of TpQ with available data to produce gradients at 10 ms intervals (example gradients are shown for lead V2). The difference of the gradient from the mean gradient in each 40ms segment was calculated. The standard deviation of these values was taken as a measure of action potential duration restitution heterogeneity in each lead. The mean of this was then taken as the R2I2. B. Mean data points for the individual ECG leads from the combined ICM cohorts were calculated and an area graph of the standard error of the mean has been plotted for the same representative leads as in A.

Figure 3. Endocardial and epicardial borders are drawn; then a large representative area of "normal myocardium" and a small area of "peak scar" are selected as shown in A. Software analysis identifies all voxels with signal intensity >2 standard deviations above "normal myocardium" mean
intensity and voxels with signal intensity >50% of the “peak scar” are subtracted from this to obtain the peri-infarct zone. Identified voxels that are not in the region of an infarct are discarded.

Figure 4. Scatter plot for Regional Restitution Instability Index (R2I2) in Control, Primary Study and Replication groups, the line indicates the value chosen to separate a positive and negative R2I2 result and filled squares identify patients who reached the endpoints of ventricular arrhythmia / death (Primary Study group) or ventricular arrhythmia (Replication group) during follow up.

Figure 5. Plot of Regional Restitution Instability Index (R2I2) against peri-infarct zone (PIZ) in each of the 19 Primary Study group patients for whom paired data was available. Lines are drawn at the optimal cut-off values for both parameters. A least-squares regression line demonstrates significant correlation (r=0.51, p=0.024).

Figure 6. Receiver operating characteristic curve for Regional Restitution Instability Index (R2I2) in Primary Study group: ventricular arrhythmia (VA) / death vs ventricular arrhythmia free survival.

Figure 7. Kaplan-Meier survival curve for combined Primary Study and Replication groups showing a significantly higher rate of ventricular arrhythmia in a “high risk” group with Regional Restitution Instability Index (R2I2) >=1.03 compared with the “low risk” group with R2I2 < 1.03 (p=0.003, log rank test).

Figure 8. Diagram shows the last beat of the drive train and the S1 S2 coupling interval at 400, 380, 360 and 340ms for leads V2 and III. Demonstration of regional heterogeneity in repolarisation: little change is seen in V2 and the QRS onset to T wave peak (QTp) is stable, while lead III is seen to fragment with two peaks and variable QTp. This Primary Study group patient had an R2I2 of 1.63 and had VA during follow up.
Table 1. Main characteristics of the Primary Study, Control and Replication groups.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Primary Study Group (n=26)</th>
<th>Controls (n=29)</th>
<th>p</th>
<th>Replication Group (n=40)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>66.2±1.9</td>
<td>45.3±2.5</td>
<td>&lt;0.001</td>
<td>66.2±1.5</td>
</tr>
<tr>
<td>Sex (% male)</td>
<td>96</td>
<td>59</td>
<td>0.001</td>
<td>88</td>
</tr>
<tr>
<td>QRS D (ms)</td>
<td>107±3.8</td>
<td>104±3.7</td>
<td>0.63</td>
<td>120±4.9</td>
</tr>
<tr>
<td>LVEF (%)</td>
<td>29±2.7</td>
<td>64±1.0</td>
<td>&lt;0.001</td>
<td>30-35%*</td>
</tr>
<tr>
<td>R2I2</td>
<td>1.09±0.06</td>
<td>0.63±0.04</td>
<td>&lt;0.001</td>
<td>0.99±0.05</td>
</tr>
</tbody>
</table>

Parametric data are expressed as mean±standard deviation. (Abbreviations: QRS D QRS duration, LVEF left ventricular ejection fraction, R2I2 regional restitution instability index). *The Replication group LVEF measurements were obtained from clinical echocardiogram reports that specify a LVEF range.
Table 2. Baseline characteristics of the Primary Study group split by endpoint.

<table>
<thead>
<tr>
<th>Variable</th>
<th>No VA / Death (n=20)</th>
<th>VA / Death (n=6)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>64.5±2.2</td>
<td>71.8±3.5</td>
<td>0.120</td>
</tr>
<tr>
<td>Sex (% male)</td>
<td>95</td>
<td>100</td>
<td>...</td>
</tr>
<tr>
<td>QRS D (ms)</td>
<td>107±4.7</td>
<td>108±6.3</td>
<td>0.889</td>
</tr>
<tr>
<td>LVEF (%)</td>
<td>30.5±3.3</td>
<td>25.3±3.0</td>
<td>0.414</td>
</tr>
<tr>
<td>PES result (positive/total)</td>
<td>7/20</td>
<td>4/6</td>
<td>0.348</td>
</tr>
<tr>
<td>R2I2</td>
<td>1.03±0.06</td>
<td>1.30±0.10</td>
<td>0.037</td>
</tr>
<tr>
<td>EDV index (ml/cm)</td>
<td>1.43±0.12</td>
<td>1.44±0.23</td>
<td>0.958</td>
</tr>
<tr>
<td>SV index (ml/cm)</td>
<td>0.37±0.04</td>
<td>0.39±0.06</td>
<td>0.790</td>
</tr>
<tr>
<td>Mass index (gm/cm)</td>
<td>0.80±0.04</td>
<td>0.72±0.04</td>
<td>0.342</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>170±1.7</td>
<td>173±2.2</td>
<td>0.383</td>
</tr>
<tr>
<td>Follow up (months)</td>
<td>24[17]</td>
<td>19 [12]</td>
<td>0.273</td>
</tr>
<tr>
<td>PIZ %*</td>
<td>7.4[8.0]</td>
<td>15.6[4.6]</td>
<td>0.016</td>
</tr>
<tr>
<td>PIZ mass (gm)*</td>
<td>7.4[7.9]</td>
<td>20.1 [7.5]</td>
<td>0.033</td>
</tr>
<tr>
<td>PIZ mass/Scar Mass %*</td>
<td>66[64]</td>
<td>72[26]</td>
<td>0.643</td>
</tr>
<tr>
<td>Scar % LV mass*</td>
<td>8.7[13.5]</td>
<td>22.0[3.8]</td>
<td>0.042</td>
</tr>
</tbody>
</table>

Parametric data are expressed as mean ± standard deviation; non-parametric data as median [interquartile range]. (Abbreviations: QRS QRS duration, LVEF left ventricular ejection fraction, PES programmed electrical stimulation, R2I2 regional restitution instability index, EDV left ventricular end diastolic volume, SV stroke volume, PIZ peri-infarct zone). *CMR peri-infarct zone data was available for 19/26 patients.
Figures

Figure 1

A Lead V2, S2 at 400 ms

B S2 at 320 ms

TpQ, QTp

TpQ = QQ - QTp, QTp

Diagram showing waveforms for different time intervals with annotations for TpQ and QTp.
Figure 3
Figure 4

![Graph showing regional restitution instability index with data points labeled ICM, Control, and Endpoint. The x-axis represents Control, Primary Study, and Replication, while the y-axis represents the regional restitution instability index. The line at R2I2 = 1.03 is marked.](image-url)
Figure 6

Primary Study Group: Endpoint VA / Death

AUC = 0.792
Figure 7

Survival free of VA/ death

Follow Up (years)

p = 0.003, log rank test

R2I2 < 1.03

R2I2 >= 1.03